Cellectar Biosciences(DE:NV40)
€0.290.00 (0.00%)
DE:NV40
Cellectar Biosciences financials statements
€0.29
At close:0.00 (0.00%)
Cellectar Biosciences (NV40) Ratios
1 Followers
Cellectar Biosciences Ratios
DE:NV40's free cash flow for Q3 2026 was $-9.41M. For the 2026 fiscal year, DE:NV40's free cash flow was increased by $0.00 and operating cash flow was $-9.41M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.96 | 2.58 | 0.41 | 1.78 | 9.16 |
| Quick Ratio | 2.96 | 2.58 | 0.41 | 1.78 | 9.16 |
| Cash Ratio | 2.78 | 2.48 | 0.38 | 1.73 | 8.95 |
| Solvency Ratio | -4.27 | -3.96 | -1.65 | -2.63 | -5.77 |
| Operating Cash Flow Ratio | -4.87 | -5.07 | -1.28 | -2.19 | -5.66 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 8.98M | $ 13.07M | $ -15.40M | $ 8.48M | $ 32.41M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.02 | 0.05 | 0.03 | 0.01 |
| Debt-to-Equity Ratio | 0.04 | 0.03 | -0.04 | 0.06 | 0.01 |
| Debt-to-Capital Ratio | 0.04 | 0.03 | -0.04 | 0.06 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.51 | 1.78 | -0.88 | 2.26 | 1.13 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.16 | 0.40 | 1.36 | 2.57 | 1.63 |
| Net Debt to EBITDA | 0.59 | 0.52 | 0.23 | 0.67 | 1.48 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.15% | 99.86% | 99.81% | 100.00% |
| EBT Per EBIT | 94.83% | 85.97% | 109.93% | 110.55% | 99.96% |
| Return on Assets (ROA) | -145.48% | -175.01% | -354.19% | -147.26% | -64.84% |
| Return on Equity (ROE) | -219.69% | -311.87% | 310.45% | -333.42% | -73.00% |
| Return on Capital Employed (ROCE) | -224.66% | -321.87% | 293.31% | -285.62% | -72.66% |
| Return on Invested Capital (ROIC) | -222.48% | -320.19% | 294.21% | -283.65% | -72.36% |
| Return on Tangible Assets | -145.48% | -175.01% | -354.19% | -147.26% | -64.84% |
| Earnings Yield | -283.20% | -407.13% | -126.34% | -263.51% | -65.84% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2462.42 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 2462.42 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -8.86 | -38.98 | -79.48 | -107.24 | -121.96 |
| Free Cash Flow Per Share | -8.87 | -39.06 | -81.60 | -108.20 | -122.72 |
| Dividend Paid and CapEx Coverage Ratio | -3931.67 | -456.66 | -37.47 | -111.62 | -159.65 |
| Capital Expenditure Coverage Ratio | -3931.67 | -456.66 | -37.47 | -111.62 | -159.65 |
| Operating Cash Flow Coverage Ratio | -56.44 | -96.32 | -58.55 | -41.77 | -74.80 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -300.53% | -435.49% | -98.19% | -210.92% | -61.98% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.35 | -0.25 | -0.79 | -0.38 | -1.52 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.78 | 0.77 | -2.46 | 1.27 | 1.11 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.33 | -0.23 | -1.02 | -0.47 | -1.61 |
| Price-to-Operating Cash Flow Ratio | -0.33 | -0.23 | -1.05 | -0.48 | -1.62 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | 0.04 | -0.10 | 0.04 |
| Enterprise Value Multiple | 0.24 | 0.27 | -0.64 | 0.25 | -0.05 |
| Enterprise Value | -5.09M | -11.84M | 24.84M | -7.20M | 1.24M |
| EV to EBITDA | 0.24 | 0.27 | -0.64 | 0.25 | -0.05 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.22 | 0.25 | -0.75 | 0.28 | -0.05 |
| EV to Operating Cash Flow | 0.22 | 0.25 | -0.77 | 0.29 | -0.05 |
| Tangible Book Value Per Share | 3.80 | 11.71 | -33.82 | 40.54 | 178.57 |
| Shareholders’ Equity Per Share | 3.80 | 11.71 | -33.82 | 40.54 | 178.57 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -8.35 | -36.52 | -104.99 | -135.18 | -130.35 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.10 | 1.11 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.06 | 1.07 | 0.76 | 0.88 | 0.94 |
Currency in USD
